Charles River Laboratories International (NYSE:CRL) Given New $173.00 Price Target at Robert W. Baird

Charles River Laboratories International (NYSE:CRL) had its price target lowered by Robert W. Baird from $177.00 to $173.00 in a research note published on Thursday,Benzinga reports. The brokerage currently has a neutral rating on the medical research company’s stock.

A number of other brokerages also recently commented on CRL. Evercore ISI boosted their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research note on Thursday, November 7th. Morgan Stanley decreased their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 5th. Bank of America cut their target price on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. The Goldman Sachs Group decreased their price target on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Finally, JPMorgan Chase & Co. lowered their price target on shares of Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating on the stock in a report on Monday, February 3rd. Three investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $195.71.

Charles River Laboratories International Price Performance

Shares of CRL stock opened at $162.63 on Thursday. Charles River Laboratories International has a twelve month low of $150.79 and a twelve month high of $275.00. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The stock has a fifty day simple moving average of $173.39 and a two-hundred day simple moving average of $188.81. The stock has a market capitalization of $8.32 billion, a price-to-earnings ratio of 20.35, a P/E/G ratio of 6.01 and a beta of 1.37.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. During the same period in the previous year, the company posted $2.46 earnings per share. The firm’s quarterly revenue was down 1.1% on a year-over-year basis. On average, analysts predict that Charles River Laboratories International will post 10.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Charles River Laboratories International

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CRL. Versant Capital Management Inc grew its stake in Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 150 shares during the last quarter. Pinnacle Bancorp Inc. lifted its holdings in shares of Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after purchasing an additional 65 shares during the period. Assetmark Inc. boosted its position in Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after buying an additional 173 shares during the last quarter. Optiver Holding B.V. acquired a new position in Charles River Laboratories International in the 4th quarter worth approximately $37,000. Finally, GeoWealth Management LLC raised its position in Charles River Laboratories International by 311.5% during the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock worth $46,000 after buying an additional 190 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).